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Abstract
Background—The purpose of this study was to determine whether baseline salivary 
inflammatory biomarkers could discriminate between different clinical levels of disease and/or 
predict clinical progression over a 3-week stent-induced biofilm overgrowth (SIBO) period.
Materials and Methods—168 participants were enrolled in a 21-day experimental gingivitis 
investigation and grouped according to clinical measures of periodontal status of health and 
diseased individuals representing each of five biofilm gingival interface (BGI) periodontal groups 
(H, G, P1, P2, P3). Stents were used to prevent plaque removal during brushing over one 
maxillary and one mandibular posterior dental sextant for 21 days. Clinical periodontal parameters 
and unstimulated saliva were collected at screening, baseline, and each week during SIBO. Saliva 
samples were assessed for levels of 13 different biomarkers by multiplex immunoassay.
Results—Higher salivary levels of interleukin (IL)-1β, matrix metalloproteinase (MMP)-3, 
MMP-8, MMP-9, and neutrophil gelatinase-associated lipocalin (NGAL) were found in diseased 
groups compared to healthy at baseline. Conversely, higher IL-1 receptor antagonist (ra) levels 
were found in healthy patients at baseline. In addition, during SIBO MMP-1, tissue inhibitor of 
metalloproteinase (TIMP)-1, and TIMP-2 levels increased across all participant groups. A 
stepwise linear regression model using all salivary biomarkers demonstrated that at baseline 
increased IL-1ra (p=0.0044) and IL-6 (p=0.0093) were the two best predictors of change in 
probing depths during SIBO.
Conclusions—In summary, this investigation supports salivary levels of IL-1ra and IL-6 as 
potential indicators for significant probing depth changes during induced gingival inflammation. 
In addition, participants from BGI-P3 group (severe periodontitis) demonstrated elevated baseline 
levels of IL-1β, MMP-3, MMP-8, MMP-9, and NGAL compared to other study groups 
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strengthening the relevance of participant's biological phenotype on salivary biomarkers 
expression
Introduction
The potential application of saliva-based diagnostic tests for periodontal disease represents 
an exciting new opportunity for chair-side diagnostics based on its non-invasive 
characteristics. Combining fast turnaround with non-invasive sampling will enable clinicians 
to stratify patients by risk and allocate treatment accordingly. Recent reports have 
demonstrated that salivary and biofilm biomarkers offer potential for the identification of 
periodontal disease progression or stability.1, 2 However, despite advances in research 
methodology and laboratory assays in order to identify biomarkers associated with chronic 
periodontal disease, it is still unclear how to effectively utilize this technology for disease 
diagnosis and detection of disease activity.
Periodontitis is both a polymicrobial and multifactorial disease where clinical measures, 
such as pocket depth (PD), clinical attachment level (CAL) and bleeding on probing (BOP), 
provides retrospective history of disease and current status, but has limited predictive value. 
A cross-sectional data analysis identified putative biomarkers from saliva and anaerobic 
pathogens that were strongly related to disease status.3 Recently, a longitudinal study 
evaluating the potential for prediction of periodontal disease progression demonstrated that 
saliva and biofilm biomarkers offer potential for the identification of periodontal disease 
activity.1
Given the complex nature of periodontal disease, a precise evaluation of periodontal disease 
activity becomes a clinical challenge. To date, limited longitudinal studies have been 
conducted to identify biomarkers that predict disease progression prior to radiographic and 
clinical manifestations.1, 4, 5 Still seeking to speed the translation of research results into 
therapies, an alternative methodology to evaluate periodontal disease activity is through the 
experimental gingivitis design. Contemporary experimental gingivitis studies have 
incorporated stents to encourage compliance, a method termed stent-induced biofilm 
overgrowth (SIBO), and to evaluate periodontal disease activity in participants with pre-
existing periodontal disease.6-8 It has been reported that gingival crevicular fluid (GCF) 
analysis can indicate differences within specific inflammatory mediators that reflect the 
magnitude of the clinical changes seen in this gingivitis induction model.8
The aim of this study was to understand whether salivary biomarkers can be used to 
discriminate among health, gingivitis, and three levels of chronic periodontitis severity and 
whether salivary biomarkers can predict periodontal disease activity during SIBO.
Materials & Methods
Patient Population
One hundred sixty eight participants were recruited and inform consent was obtained at the 
Center for Oral and Systemic Diseases clinic between 2005-2007 (University of North 
Carolina, Chapel Hill, North Carolina). The study was approved by the University of North 
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Carolina Health Sciences Institutional Review Board. Individuals age 18 years and older 
were eligible for the study. All individuals were required to have at least four teeth in the 
functional dentition with a minimal of three adjacent teeth with interproximal papilla in each 
posterior sextant receiving the SIBO, not received periodontal treatment or antibiotic 
therapy for medical or dental reasons for 1 month prior to the start of the investigation, and 
not taking long-term medications affecting periodontal status, including calcium antagonists, 
anticonvulsives, immunosuppressives, and anti-inflammatory medications. Exclusion 
criteria included a history of metabolic bone diseases, autoimmune diseases, unstable 
diabetes, or post-menopausal osteoporosis. Pregnant or lactating women were not allowed to 
participate in the study. Smokers and individuals with diabetes were not excluded, with no 
stratification performed on these risk factors.
Study Design
This prospective cohort study involved the induction of experimental biofilm overgrowth 
using stents as recently described.8 All teeth were assessed for periodontal clinical measures 
by calibrated examiners. Clinical parameters including PD, CAL, and BOP, were measured 
at six sites per tooth. Other clinical assessments included measures of plaque accumulation 
(PI)9 and gingival inflammation index (GI). 10Based on clinical assessments, patients were 
enrolled in one of the following five categories: (1) Biofilm Gingival Interface (BGI) health 
(H), all PD<3mm, BOP<10%; (2) BGI-gingivitis (G), all PD<3mm, BOP≥10%; (3) BGI-P1 
(P1), 1+ site with PD>3mm, BOP≤10%; (4) BGI-P2 (P2), 1+ site with PD>3mm, BOP>10% 
but BOP≤50%; (5) BGI-P3 (P3), 1+ site with PD>3mm, BOP>50%. These five categories 
are clearly different from traditional definitions of health, gingivitis, mild periodontitis, 
moderate periodontitis, and severe periodontitis as they considered use BOP and PD only. 
The BGI categories display a similar gradient with increasing severity and extent of clinical 
signs from BGI-H through BGI-P3 categories and reflect current periodontal status rather 
than historical levels of disease activity.11
Figure 1 illustrates the timeline of the study. After a prophylaxis at (−) 2weeks, participants 
received acrylic stents at the baseline visit to be worn only during their oral hygiene routine 
in order to abstained from brushing and flossing teeth in one maxillary and one mandibular 
posterior sextant during a three- week period. The sextants selected were the right maxillary 
and mandibular sextants, except when fewer than four teeth were present in one posterior 
sextant. If there were fewer than 4 teeth in a right posterior sextant, the opposing posterior 
sextant was used for the stent placement. Patients were monitored for safety every week and 
after the induction of experimental biofilm overgrowth through 21 days, participants 
reinstituted normal full mouth oral hygiene and daily plaque control. Participants were 
followed for the next four weeks during gingivitis resolution. Prophylaxis with scaling and 
root planing were performed at completion of the study. The investigation was a single 
masked study. Participants were excluded from the study or analysis if any of the following 
conditions applied: (1) changes in the participant's medical status or medications that were 
not negligible; (2) use of antibacterial rinses; (3) use of dentifrices, toothbrush, dental floss, 
or any irrigation device during the non-hygiene phase of the study; (4) participant's inability 
or noncompliance to wear their stents or shields over one mandibular and one maxillary 
sextant during daily brushing procedures;(5) use of oral antibiotics and non-steroidal anti-
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inflammatory drugs; (6) participants requiring treatment for an acute medical or dental 
condition during the study were withdrawn from the investigation. Any site undergoing PD 
increase of > 2 mm from the baseline measurement was deemed as “progressing” and 
participant was exited from the study and given scaling and root planing treatment as a 
rescue therapy.
Whole Saliva Collection and Analysis
Unstimulated whole saliva was collected at the beginning of each study visit with passive 
drooling into sterile plastic tubes from all patients.12 At each time point, approximately 3 
mL of unstimulated saliva were collected into a 15 mL plastic conical tube. Participants 
refrained from eating, drinking, chewing gum, breath mints, or performing oral hygiene 
procedures for at least one hour prior to saliva collection. Samples were further placed on 
ice and aliquoted prior to storage at -80°C. Whole saliva samples were tested for the 
presence of interleukin (IL)-1β, IL-1 receptor antagonist (ra), IL-8, monocyte 
chemoattractant protein-1 (MCP-1), matrix metalloproteinase (MMP)-1, MMP-3, MMP-8, 
MMP-9, tissue inhibitor of metalloproteinase (TIMP)-1, TIMP-2, TIMP-3, and TIMP-4.
In this study, 3-ml unstimulated saliva was analyzed in duplicate for samples collected at 
Days 0 (Baseline) and 21 (peak induction) for IL-1β, IL-1ra, IL-8, MCP-1, MMP-1, 
MMP-3, MMP-8, MMP-9, TIMP-1-4 using a Bio-Plex 2000 multiplex format.§ Neutrophil 
gelatinase-associated lipocalin (NGAL) levels were measured by ELISA.§ After thawing, 
each sample was re-centrifuged again and diluted with assay buffer according to the 
manufacturer's recommendations for serum sample analysis. Local levels of inflammatory 
biomarkers were determined following methods described by Offenbacher et al.8 The 
following list of biomarkers were assayed followed by the mean minimum detection level in 
picograms per milliliter shown in brackets []: IL-1β [0.27], IL-8 [5.3], MCP-1 [0.16], 
MMP-1 [4.4], MMP-3 [1.3], MMP-8 [8.9], MMP-9 [7.4], TIMP-1 [230], TIMP-2 [730], 
TIMP-3 [2300], TIMP-4 [120], IL-1ra [2.06] and NGAL [7.8]. Volumes of 100 μl were used 
for each panel of mediators. All mediator values were corrected for assay dilution and 
expressed as a saliva concentration. Mean values and standard deviations were computed for 
stent sites for each patient at each visit. Log mean values of mediator concentrations were 
computed for comparisons, as the mean values were not normally distributed.
Statistical Methods
Statistical analyses and data management were performed using SAS║. Statistical 
significance was set at p<0.05, and the unit of analysis was the individual participant. A pre-
study power analysis indicated a minimum sample size of eight test/control pairs to yield 
power of 90% with alpha of 5% for IL-1β changes. In four pairs of samples tested in 
replicate, the mean inter-group difference in IL-1β expression was 10.7 with a standard 
deviation of 16.0. Therefore, the intended sample of 30 participants per group would be 
sufficient to detect differences in the expression of individual inflammatory markers of 
interest from baseline to induction of SIBO. The expected magnitude of the changes and the 
§(R&D Systems, Minneapolis, MN, USA)
║(SAS Institute, Inc., Cary, NC, USA, version 9.1.3)
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variance in other biomarkers were unknown. For this reason, a minimum of thirty three 
participants were enrolled per group for a total of 168 participants. Statistical comparisons 
were made using chi-square for categorical variables and ANOVA for continuous variables. 
Clinical and biochemical changes were analyzed across groups using a mixed-models 
analysis. For mediators that showed overall significance between groups, generalized linear 
modeling allowed analysis of each mediator independent of changes of the others. Changes 
in clinical signs were used to identify high and low responders for each of the BGI 
conditions based upon the clinical response to biofilm overgrowth dichotomizing on the 
median change in clinical sign at 21 days as compared to baseline.
Results
A total of 299 patients were screened for study eligibility; of these, 170 patients met all 
study criteria and were evenly distributed among the five BGI categories. During the study 
two participants, both from the H and P1 group respectively, withdrew before study 
completion. Demographics baseline characteristics of this cohort have been described in 
Table 1. The mean age for participants differed significantly between H and G compared to 
P1, P2, and P3 (p=0.01). Sixty- seven percent overall were female. Only participants in 
group G were of normal weight by body mass index (BMI<25kg/m2); all the other BGI 
groups were overweight, particularly P2 and P3. Overall 60.1% were African-Americans. 
Twelve percent of the population were current cigarette smokers, and they were evenly 
distributed in all BGI groups. Only 4% of the population were diabetic and no significant 
difference was detected in the distribution among the BGI groups. The clinical presentation 
of the study participants at baseline is described in Table 2. As expected, at baseline, plaque 
scores and BOP were significantly lower in H, and P1 than in the other BGI groups. As 
anticipated, P2 and P3 presented with significantly higher GI scores than P1. Similarly, P1, 
P2, and P3 presented with increased mean CAL ≥ 3mm and PD ≥ 4mm in comparison to H 
and G. No participants were exited due to increasing of PD > 2mm. Participants with 
increasing PD during the SIBO were found to respond to therapy at exit with PD returning 
to baseline or improving from baseline. No participants experienced irreversible loss of 
attachment.
Baseline Results Comparing Salivary Biomarkers
The baseline log10 mean (StdErr) values by BGI category of salivary biomarker levels 
comparing the five groups are shown in Table 3. An analysis of variance (ANOVA) was 
performed to detect differences between groups adjusted by Bonferroni correction. 
Significant differences were found at baseline between groups for IL-1β, MMP-3, MMP-8, 
MMP-9, TIMP-3, and NGAL. BGI P3 participants had significantly higher log mean values 
compared to other groups for IL-1β, MMP-3, MMP-8, MMP-9, and NGAL. Compared to H 
participants, P3 participant levels were more than two-fold elevated for IL-1β, MMP-3, 
MMP-9, and TIMP-3, and more than five-fold elevated for MMP-8. Mean TIMP-3 was 
significantly lower for P2 compared to other groups.
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Clinical and Salivary Biomarker Responsiveness to Biofilm Overgrowth
Overall, participants showed significant increases in PI, GI, and BOP across all groups 
during the stent induction period (Table 4) (p < 0.05). The group G participants also showed 
a slight but statistically significant increase in attachment loss (p=0.03) during SIBO. 
Similarly, P1 participants showed a small, but significant increase in PD measurements 
(p=0.047). When grouped together, H and G participants showed significant increased PI, 
GI, BOP, and PD (p < 0.05). By contrast, P1-P3 grouped together only demonstrated 
significant increased PI, GI, and BOP during SIBO (p < 0.05). P2 and P3 showed no 
changes in probing depths or attachment levels.
During SIBO, pooling all participants, there were significant increases in salivary 
concentrations from baseline to peak induction for MMP-1, TIMP-1, and TIMP-2 (p < 
0.0038) (Table 5). After adjusting by Bonferroni analysis, TIMP-4 did not meet statistical 
significance. When subdivided by disease category there were no significant changes in 
salivary biomarker levels during SIBO induction. In addition, no mediator showed a 
significant decrease during the biofilm overgrowth phase.
Baseline Salivary Biomarkers Predictors of Clinical Changes
A stepwise linear regression model was used to evaluate the ability of salivary biomarkers to 
estimate changes in clinical periodontal parameters. From all salivary biomarkers analyzed 
in the study, IL-1ra (p=0.0044) and IL-6 (p=0.0093) were the two best predictors of change 
in probing depths during the SIBO, with an overall r2 value of 0.37. The effect slope for 
IL-1ra was positive (0.675) and negative for IL-6 (-0.246). The results from this study 
demonstrated no significant salivary predictors of changes in BOP, GI, or CAL.
Discussion
In this study we sought to examine the ability of salivary biomarkers to discriminate 
different periodontal clinical phenotypes and to evaluate a patient's risk of active periodontal 
disease as related to PD changes during SIBO. Results demonstrated significant differences 
in baseline salivary biomarkers among participant groups, but no differences in response to 
SIBO. This finding differs from other SIBO studies of cytokine changes in gingival 
crevicular fluid, suggesting that saliva, although a convenient sample, is not as sensitive to 
clinical changes as GCF. This is logical, since the salivary cytokines arguably represent a 
pooled GCF sample, which is rich in cytokines. Moreover, mucosal and salivary gland 
tissues can contribute to salivary cytokines.13 The BGI classification11, adopted in this 
study, was intended to segregate participants into disease categories with more homogenous 
biological phenotypes. This was partially achieved, as there were differences in salivary 
biomarkers at baseline across groups. However, it is interesting to note that significant 
clinical changes were only observed among the H and G participants that experienced 
transient increases in PD. Conversely, there were changes in cytokine response that related 
to clinical changes which occurred across categories.
As previously described by our group, stent-induced biofilm overgrowth in a model of 
experimental gingivitis is associated with marked, but reversible increases in the 
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concentrations of cytokines and concomitant suppression of multiple chemokines present in 
gingival crevicular fluid.8 In this investigation we did not see those cytokine and chemokine 
changes in saliva samples. An experimental gingivitis study reported by Lee and 
colleagues14 also identified specific salivary biomarker and microbial signatures that are 
associated with gingival inflammation. However, only participants with healthy periodontal 
clinical phenotype and no history of periodontal tissue loss were included in the study. To 
the best of our knowledge, this study is unique in that it provides an analysis of host-
response biomarker signatures associated with five different biological phenotypes during 
stent-induced biofilm overgrowth and its association with active inflammatory processes in a 
longitudinal study.
During periodontal disease, host inflammatory cells are recruited, and inflammatory 
cytokines are released from fibroblasts, macrophages, connective tissue, and junctional 
epithelial cells. Consequently, host-derived enzymes, such as MMP-8 and MMP-9, are 
released by PMNs and osteoclasts, leading to connective tissue and alveolar bone 
degradation. Currently, studies have demonstrated the association of host-response salivary 
biomarkers with periodontal disease.3, 15, 16 Our results showed obvious differences at 
baseline between P3 group and all other participants (Table 3). The finding of significant 
differences in IL-1β, MMP-3, MMP-8, MMP-9, TIMP-3, and NGAL between groups is in 
contrast to Teles and collaborators 17, who found no significant differences in salivary 
granulocyte-macrophage colony-stimulating factor, IL-1β, IL-2, IL-4, IL-5, IL-6, IL-8, 
IL-10, IFNγ, or TNF-α between healthy and periodontitis participants. Though, those 
participants were grouped by periodontal clinical phenotype rather than BGI classification. 
Conversely, our results are in accordance with several other studies showing higher levels of 
IL-1β5, 15, 18-21, MMP-83, 22, 23, MMP-9 23, and NGAL24 in the saliva of gingivitis and 
periodontitis participants.
Several mediators, including MMP-1, TIMP-1, and TIMP-2 increased significantly from 
baseline to peak of induction at day 21 (Table 5). To our knowledge, this is the first human 
study demonstrating changes in TIMPs during experimental gingivitis. The increased levels 
of TIMPs may be due to a local response to dampen inflammation and prevent protein 
degradation. MMPs are generally produced in an inactive (preMMP) form and must be 
cleaved to become functional. It is possible that a collagenolytic activity assay of saliva 
would be more useful than one measuring collagenase concentration alone. In an attempt to 
validate a soluble biotinylated-collagen assay, Mancini and collaborators 25 found 
significant differences in GCF MMP-8 activity from periodontitis patients at baseline, re-
evaluation, and maintenance visits. In a different study, the same group showed that the 
activity levels of MMPs did not correlate significantly with Western blot analysis of 
zymogen versus active form.26 Our results demonstrated that MMP-3, MMP-8, and MMP-9 
did not significantly increase during induced gingivitis. A Possible explanation is that initial 
changes are mostly expressed by enzymes being cleaved into their active forms. In addition, 
a three-week study may be too short to induce measurable changes in the amounts of these 
enzymes.
Increases in plaque, gingival index, and bleeding on probing across all groups are to be 
expected in an experimental gingivitis study. Our results, in accordance with the 
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literature 8, 27, demonstrated significant increases in PI, GI, and BOP at day 21 compared to 
baseline (Table 4). participants under the P3 classification did not demonstrate significant 
changes regarding GI and BOP at day 21. This can be expected by the fact that to be 
classified under this biologic phenotype category, participants must have more than 50% 
BOP sites at baseline.
In our study, baseline IL-1ra and IL-6 levels were found to be significant predictors of 
change in PD. IL-1ra is the antagonist for IL-1β receptor, blocking its action. As IL-1β is a 
pro-inflammatory molecule, high levels of its receptor antagonist could indicate a 
compensatory mechanism of negative feedback or the release of molecules that are normally 
tissue-bound. IL-6 is known to be a pro-inflammatory molecule that shifts the immune 
response towards a cell-mediated reaction. A study demonstrated that IL-6 is elevated in 
participants with chronic periodontitis and decreases after periodontal therapy.28 Our results 
showed that IL-6 was not significantly different between groups at baseline. However, high 
IL-6 levels at baseline were able to predict an increase in PD. Recently, Giannobile and 
collaborators demonstrated that patients with high baseline levels of salivary IL-6 and 
MMP-1 are at higher risk for developing a heightened gingival inflammatory response 
compared to individuals displaying low levels of these biomarkers.14
In summary, this investigation supports salivary levels of IL-1ra and IL-6 as potential 
indicators for significant probing depth changes during induced gingival inflammation. In 
addition, P3 participants demonstrated elevated baseline levels of IL-1β, MMP-3, MMP-8, 
MMP-9, and NGAL compared to other study groups strengthening the relevance of 
participant's biological phenotype on salivary biomarkers expression. Clinical implications 
include improved patient monitoring and control of disease activity. Future large study 
populations will be needed to validate the use of salivary biomarkers to identify susceptible 
patients in order to provide them preventive therapy to avoid irreversible periodontal 
breakdown.
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Study timeline illustrating data collection and treatment delivery during running and 
resolution phase. SCR: screening, Prophy: adult prophylaxis or scaling and root planing, 
SIBO: stent-induced biofilm overgrowth, Clinical: probing depth, clinical attachment level, 
bleeding on probing, plaque index, gingival index, WS: whole saliva.
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Table 4
Mean (StdErr) delta clinical sign (Day 21-Day 0) during SIBO by BGI group
BGI Category Mean (StdErr) p value
BGI (Health)
Plaque 0.85 (0.11) <0.0001
Gingival Index 0.44 (0.06) <0.0001
Bleeding On Probing 19.4 (4.03) <0.0001
Probing Depth (mm) 0.05 (0.06) 0.46
Attachment Level (mm) -0.08 (0.05) 0.12
BGI (Gingivitis)
Plaque 0.79 (0.09) <0.0001
Gingival Index 0.29 (0.05) <0.0001
Bleeding On Probing 20.5 (3.49) <0.0001
Probing Depth (mm) 0.18 (0.09) 0.052
Attachment Level (mm) -0.11 (0.05) 0.03
BGI (P1)
Plaque 0.70 (0.10) <0.0001
Gingival Index 0.21 (0.05) 0.0001
Bleeding On Probing 21.0 (4.47) <0.0001
Probing Depth (mm) 0.11 (0.05) 0.047
Attachment Level (mm) 0.01 (0.05) 0.91
BGI (P2)
Plaque 0.82 (0.10) <0.0001
Gingival Index 0.28 (0.06) 0.0001
Bleeding On Probing 15.7 (4.05) 0.0005
Probing Depth (mm) 0.03 (0.06) 0.67
Attachment Level (mm) 0.03 (0.06) 0.63
BGI (P3)
Plaque 0.65 (0.08) <0.0001
Gingival Index 0.15 (0.04) 0.002
Bleeding On Probing 8.30 (4.47) 0.07
Probing Depth (mm) -0.06 (0.06) 0.30
Attachment Level (mm) 0.02 (0.08) 0.79
BGI (Health + Gingivitis)
Plaque 0.82 (0.07) <0.0001
Gingival Index 0.37 (0.04) <0.0001
Bleeding On Probing 19.9 (2.67) <0.0001
Probing Depth (mm) 0.11 (0.05) 0.04
Attachment Level (mm) -0.09 (0.03) 0.008
BGI (P1-P3)
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BGI Category Mean (StdErr) p value
Plaque 0.73 (0.05) <0.0001
Gingival Index 0.22 (0.03) <0.0001
Bleeding On Probing 15.8 (2.51) <0.0001
Probing Depth (mm) 0.02 (0.03) 0.48
Attachment Level (mm) 0.02 (0.04) 0.66
StdErr = Standard error
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Table 5
Mixed models: Log10 mean (StdErr) saliva mediator by time point.
Baseline Peak p-value
IL-1b 2.51 (0.03) 2.50 (0.03) 0.60
IL-8 2.81 (0.03) 2.82 (0.03) 0.73
MCP-1 2.43 (0.03) 2.44 (0.03) 0.39
MMP-1 1.34 (0.08) 1.51 (0.08) 0.002
MMP-3 2.01 (0.05) 1.97 (0.04) 0.39
MMP-8 4.94 (0.05) 4.89 (0.05) 0.20
MMP-9 5.05 (0.04) 5.07 (0.04) 0.55
TIMP-1 5.20 (0.02) 5.28 (0.02) 0.0002
TIMP-2 4.52 (0.02) 4.60 (0.02) <0.0001
TIMP-3 1.50 (0.11) 1.56 (0.11) 0.12
TIMP-4 1.10 (0.02) 1.15 (0.02) 0.03
IL-1ra 5.70 (0.03) 5.72 (0.02) 0.42
NGAL 2.58 (0.02) 2.57 (0.02) 0.76
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